We are advised by Arkbio that journalists and other readers should disregard the news release, Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD, issued on Jan. 6, 2026 by Arkbio over PR Newswire, as the release contained inappropriate information.
source: Arkbio
【你點睇？】日本國會通過法案設立「國家情報局」，你認為日本此舉主要目的是？你是否擔心日本近年軍事及情報能力持續擴張？► 立即投票
